Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$26.38
-0.1%
$23.55
$14.40
$31.66
$1.75B1.331.04 million shs927,305 shs
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$9.16
+0.1%
$8.10
$4.02
$12.73
$488.70M2.041.21 million shs769,183 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$188.23
-0.2%
$176.18
$140.68
$189.92
$453.32B0.48.94 million shs5.66 million shs
MannKind Corporation stock logo
MNKD
MannKind
$5.66
-1.7%
$4.66
$3.38
$7.63
$1.74B1.082.85 million shs3.39 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
0.00%+1.03%+15.48%+25.88%-13.83%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
0.00%+2.47%+20.56%+37.56%-2.46%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+4.91%+5.79%+21.44%+17.60%
MannKind Corporation stock logo
MNKD
MannKind
0.00%+4.16%+3.97%+62.71%-11.25%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$26.38
-0.1%
$23.55
$14.40
$31.66
$1.75B1.331.04 million shs927,305 shs
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$9.16
+0.1%
$8.10
$4.02
$12.73
$488.70M2.041.21 million shs769,183 shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$188.23
-0.2%
$176.18
$140.68
$189.92
$453.32B0.48.94 million shs5.66 million shs
MannKind Corporation stock logo
MNKD
MannKind
$5.66
-1.7%
$4.66
$3.38
$7.63
$1.74B1.082.85 million shs3.39 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
0.00%+1.03%+15.48%+25.88%-13.83%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
0.00%+2.47%+20.56%+37.56%-2.46%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.00%+4.91%+5.79%+21.44%+17.60%
MannKind Corporation stock logo
MNKD
MannKind
0.00%+4.16%+3.97%+62.71%-11.25%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
2.67
Moderate Buy$46.1374.85% Upside
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
2.33
Hold$13.5047.38% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.68
Moderate Buy$189.120.47% Upside
MannKind Corporation stock logo
MNKD
MannKind
3.00
Buy$11.1797.29% Upside

Current Analyst Ratings Breakdown

Latest EBS, JNJ, CLDX, and MNKD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetMarket Perform$172.00 ➝ $193.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$198.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetEqual WeightOverweight$170.00 ➝ $212.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual WeightOverweight$170.00 ➝ $212.00
10/3/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$175.00 ➝ $198.00
9/30/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price Target$188.00 ➝ $210.00
9/27/2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/27/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
9/27/2025
MannKind Corporation stock logo
MNKD
MannKind
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/23/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$167.00 ➝ $206.00
(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
$7.02M249.56N/AN/A$11.26 per share2.34
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
$812.50M0.60$1.92 per share4.76$8.91 per share1.03
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$90.63B5.00$13.09 per share14.38$29.69 per share6.34
MannKind Corporation stock logo
MNKD
MannKind
$285.50M6.08$0.14 per share41.50($0.29) per share-19.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
-$190.60M$2.453.744.43N/A16.38%24.63%8.97%11/5/2025 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$9.3520.1317.002.4025.00%32.49%13.00%10/14/2025 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1151.4624.61N/A10.87%-32.60%7.81%11/6/2025 (Estimated)

Latest EBS, JNJ, CLDX, and MNKD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/14/2025Q3 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.78N/AN/AN/A$23.73 billionN/A
8/7/2025Q2 2025
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million
8/6/2025Q2 2025
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
-$0.26$0.16+$0.42-$0.22$148.55 million$140.90 million
8/6/2025Q2 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.04$0.05+$0.01N/A$77.82 million$76.53 million
7/16/2025Q2 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/AN/AN/AN/AN/A
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.76%N/A55.61%64 Years
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A

Latest EBS, JNJ, CLDX, and MNKD Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.35%8/26/20258/26/20259/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
19.67
19.67
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
1.25
5.66
3.00
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.50
1.01
0.76
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.50
2.24

Institutional Ownership

CompanyInstitutional Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
N/A
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
78.40%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
MannKind Corporation stock logo
MNKD
MannKind
49.55%

Insider Ownership

CompanyInsider Ownership
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
4.40%
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
1.20%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
MannKind Corporation stock logo
MNKD
MannKind
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
15066.41 million63.49 millionOptionable
Emergent Biosolutions Inc. stock logo
EBS
Emergent Biosolutions
2,42053.35 million51.64 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
MannKind Corporation stock logo
MNKD
MannKind
400306.83 million297.62 millionOptionable

Recent News About These Companies

MannKind (NASDAQ:MNKD) Shares Down 5% - Time to Sell?
MannKind (NASDAQ:MNKD) Insider Stuart Tross Sells 47,000 Shares

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Celldex Therapeutics stock logo

Celldex Therapeutics NASDAQ:CLDX

$26.38 -0.03 (-0.11%)
Closing price 04:00 PM Eastern
Extended Trading
$25.66 -0.72 (-2.75%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Emergent Biosolutions stock logo

Emergent Biosolutions NYSE:EBS

$9.16 +0.01 (+0.11%)
Closing price 03:59 PM Eastern
Extended Trading
$9.13 -0.03 (-0.37%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$188.23 -0.41 (-0.22%)
Closing price 03:59 PM Eastern
Extended Trading
$187.76 -0.47 (-0.25%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

MannKind stock logo

MannKind NASDAQ:MNKD

$5.66 -0.10 (-1.74%)
Closing price 04:00 PM Eastern
Extended Trading
$5.68 +0.02 (+0.35%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.